Membrane Assays to Characterize Interaction of Drugs with ABCB1.
ATP-binding cassette sub-family B member 1 (ABCB1) [P-glycoprotein (P-gp), multidrug resistance protein 1 (MDR1)] can affect the pharmacokinetics, safety, and efficacy of drugs making it important to identify compounds that interact with ABCB1. The ATPase assay and vesicular transport (VT) assay are membrane based assays that can be used to measure the interaction of compounds with ABCB1 at a lower cost and higher throughput compared to cellular-based assays and therefore can be used earlier in the drug development process. To that end, we tested compounds previously identified as ABCB1 substrates and inhibitors for interaction with ABCB1 using the ATPase and VT assays. All compounds tested interacted with ABCB1 in both the ATPase and VT assays. All compounds previously identified as ABCB1 substrates activated ABCB1-mediated ATPase activity in the ATPase assay. All compounds previously identified as ABCB1 inhibitors inhibited the ABCB1-mediated transport in the VT assay. Interestingly, six of the ten compounds previously identified as ABCB1 inhibitors activated the basal ATPase activity in activation assays suggesting that the compounds are substrates of ABCB1 but can inhibit ABCB1 in inhibition assays. Importantly, for ATPase activators the EC50 of activation correlated with the IC50 values from the VT assay showing that interactions of compounds with ABCB1 can be measured with similar levels of potency in either assay. For ATPase nonactivators the IC50 values from the ATPase inhibition and VT inhibition assay showed correlation. These results demonstrate the utility of membrane assays as tools to detect and rank order drug-transporter interactions.
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Zsolt
Z
Fekete
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Zsuzsanna
Z
Rajnai
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Tünde
T
Nagy
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Katalin Tauberné
KT
Jakab
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Anita
A
Kurunczi
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Katalin
K
Gémes
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary.
Krisztina
K
Herédi-Szabó
Institute of Pharmaceutical Chemistry, University of Szeged, 6 Eötvös St., Szeged, 6720, Hungary.
Ferenc
F
Fülöp
Department of Medical Chemistry, Faculty of General Medicine, University of Szeged, 8 Dóm tér, Szeged, 6720, Hungary.
Gábor K
GK
Tóth
XenoTech L.L.C., 16825 West 116 Street, Lenexa, KS, 66219, USA.
Maciej
M
Czerwinski
XenoTech L.L.C., 16825 West 116 Street, Lenexa, KS, 66219, USA.
Greg
G
Loewen
Solvo Biotechnology, 2 Gyár St., Budaörs, 2040, Hungary. krajcsi@solvo.com.
Peter
P
Krajcsi
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism*; D003078:Colchicine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D017239:Paclitaxel / Q000494:pharmacology
D018435:ATP Binding Cassette Transporter, Subfamily B; D000251:Adenosine Triphosphatases; D017239:Paclitaxel; D003078:Colchicine
ADME; ATPase assay; MDR1; Multidrug resistance transporters; P-gp; Vesicular transport assay